-
Innovation Ranking
NewInnovation Ranking – La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company (La Jolla) discovers, develops and commercializes biopharmaceutical products for life-threatening diseases. The company’s major product includes the US FDA approved Giapreza, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock and Xerava (eravacycline), is an injection of tetracycline class antibacterial for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its investigational product candidates include LJPC-0118 intended for the treatment of severe malaria and LJPC-401, a proprietary...
-
Product Insights
Allergic Asthma – Drugs In Development, 2023
Global Markets Direct’s, ‘Allergic Asthma - Drugs In Development, 2023’, provides an overview of the Allergic Asthma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Hospital Acquired Pneumonia (HAP) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hospital Acquired Pneumonia (HAP) - Drugs In Development, 2023’, provides an overview of the Hospital Acquired Pneumonia (HAP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Ventilator Associated Pneumonia (VAP) – Drugs In Development, 2023
Global Markets Direct’s, ‘Ventilator Associated Pneumonia (VAP) - Drugs In Development, 2023’, provides an overview of the Ventilator Associated Pneumonia (VAP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) – Drugs In Development, 2023
Global Markets Direct’s, ‘Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Drugs In Development, 2023’, provides an overview of the Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Hypotension – Drugs In Development, 2023
Global Markets Direct’s, ‘Hypotension - Drugs In Development, 2023’, provides an overview of the Hypotension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypotension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Skin And Skin Structure Infections (SSSI) Caused By Bacteria – Drugs In Development, 2023
Global Markets Direct’s, ‘Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Drugs In Development, 2023’, provides an overview of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Eravacycline Dihydrochloride in Ventilator Associated Pneumonia (VAP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eravacycline Dihydrochloride in Ventilator Associated Pneumonia (VAP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eravacycline Dihydrochloride in Ventilator Associated Pneumonia (VAP) Drug Details:...
-
Company Profile
La Jolla Pharmaceutical Company – Company Profile
La Jolla Pharmaceutical Company (La Jolla) discovers, develops and commercializes biopharmaceutical products for life-threatening diseases. The company’s major product includes the US FDA approved Giapreza, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock and Xerava (eravacycline), is an injection of tetracycline class antibacterial for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its investigational product candidates include LJPC-0118 intended for the treatment of severe malaria and LJPC-401, a proprietary...
Add to Basket -
Company Profile
Tetraphase Pharmaceuticals Inc – Company Profile
Tetraphase Pharmaceuticals Inc (Tetraphase), a subsidiary of La Jolla Pharmaceutical Company, is a pharmaceutical company that discovers and develops antibiotic resistance medicines. The company’s products under clinical development include Xerava (eravacycline), TP-271, TP-2846 and TP-6076. It develops products for the treatment of respiratory diseases caused by bacterial biothreat and antibiotic-resistant public health pathogens. Tetraphase’s eravacycline is used for the treatment of multi-drug resistant (MDR) infections which include MDR gram-negative bacteria. The company offers drugs in therapeutic areas of antibiotics, oncology...
Add to Basket